These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17046655)

  • 1. Imaging polyglutamine deposits in brain tissue.
    Osmand AP; Berthelier V; Wetzel R
    Methods Enzymol; 2006; 412():106-22. PubMed ID: 17046655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.
    Mackenzie IR; Butland SL; Devon RS; Dwosh E; Feldman H; Lindholm C; Neal SJ; Ouellette BF; Leavitt BR
    BMC Neurol; 2006 Aug; 6():32. PubMed ID: 16945149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity.
    Chen S; Berthelier V; Yang W; Wetzel R
    J Mol Biol; 2001 Aug; 311(1):173-82. PubMed ID: 11469866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polyglutamine diseases: a pathologic view].
    Yamada M
    Rinsho Shinkeigaku; 2003 Nov; 43(11):903-5. PubMed ID: 15152499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations.
    Marchut AJ; Hall CK
    Proteins; 2007 Jan; 66(1):96-109. PubMed ID: 17068817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
    Michalik A; Van Broeckhoven C
    Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SCA17, a novel polyglutamine disease caused by the expansion of polyglutamine tracts in TATA-binding protein].
    Nakamura K
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1123-5. PubMed ID: 12235815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of polyglutamine disorders: aggregation revisited.
    Michalik A; Van Broeckhoven C
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R173-86. PubMed ID: 14504263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
    McLeod CJ; O'Keefe LV; Richards RI
    Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease.
    Nguyen HP; Kobbe P; Rahne H; Wörpel T; Jäger B; Stephan M; Pabst R; Holzmann C; Riess O; Korr H; Kántor O; Petrasch-Parwez E; Wetzel R; Osmand A; von Hörsten S
    Hum Mol Genet; 2006 Nov; 15(21):3177-94. PubMed ID: 16984963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases.
    Yamada M; Tan CF; Inenaga C; Tsuji S; Takahashi H
    Neuropathol Appl Neurobiol; 2004 Dec; 30(6):665-75. PubMed ID: 15541006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A microtiter plate assay for polyglutamine aggregate extension.
    Berthelier V; Hamilton JB; Chen S; Wetzel R
    Anal Biochem; 2001 Aug; 295(2):227-36. PubMed ID: 11488626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor.
    Thakur AK; Yang W; Wetzel R
    FASEB J; 2004 May; 18(7):923-5. PubMed ID: 15001566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.
    de Cristofaro T; Affaitati A; Cariello L; Avvedimento EV; Varrone S
    Biochem Biophys Res Commun; 1999 Jun; 260(1):150-8. PubMed ID: 10381359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
    de Pril R; Fischer DF; Maat-Schieman ML; Hobo B; de Vos RA; Brunt ER; Hol EM; Roos RA; van Leeuwen FW
    Hum Mol Genet; 2004 Aug; 13(16):1803-13. PubMed ID: 15198995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal toxicity of expanded polyglutamine depends on intracellular distribution in addition to the expression level.
    Satoh M; Shimada A; Kawamura N; Chiba Y; Yoshikawa K; Ishii S; Furukawa A; Kumagai N; Hosokawa M
    Neuropathology; 2008 Oct; 28(5):485-96. PubMed ID: 18384512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic strategies for the polyglutamine diseases].
    Nagai Y; Popiel HA; Fujikake N; Toda T
    Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.